17% Weight Loss in 16 Weeks… Is This Better Than Retatrutide?

Lilly just gave us a glimpse of what could come after today’s GLP-1s, and it may not be about simply pushing patients to stronger drugs and higher doses.

This week on On The Pen: The Weekly Dose, we break down Lilly’s surprising early data combining just 5 mg of tirzepatide with 3 mg of eloralintide, producing roughly 17% weight loss in only 16 weeks. Could combinations like this eventually approach retatrutide-level efficacy with better tolerability? And when retatrutide reaches the real world, how many patients will actually need or tolerate the higher doses responsible for its biggest clinical-trial numbers?

We’re also digging into the bigger stories shaping the future of obesity medicine, including new research suggesting semaglutide may influence aging beyond calorie restriction in mice, the emerging race to preserve lean mass during GLP-1 weight loss, apitegromab’s eye-popping price, Lilly’s legal battle over retatrutide’s classification, the underground market already selling unapproved Reta, and the latest development in Lilly’s lawsuit against Mochi.

The science is getting better incredibly quickly. The bigger question may be whether we can deliver enough efficacy, tolerability and muscle preservation at a price patients can actually access.

👍 Like, comment and subscribe if you want patient-centered GLP-1 news without the pharmaceutical press-release filter. If you listen to the podcast on Apple or Spotify, leaving a rating and review is one of the best ways to help more people find On The Pen.

🔗 Everything On The Pen: linktr.ee/manonthemounjaro⁠

On The Pen: Empowering you to have better conversations with your doctor.

#GLP1 #Zepbound #Mounjaro #Retatrutide #Tirzepatide #Eloralintide #WeightLoss #ObesityMedicine #Ozempic #Wegovy